
Sign up to save your podcasts
Or


Hartmut Ehrlich, CEO of Abivax, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Abivax is working to develop treatments modulating the body’s natural immune system to treat patients with chronic inflammatory diseases, viral infections and cancer.
By John Simboli5
77 ratings
Hartmut Ehrlich, CEO of Abivax, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Abivax is working to develop treatments modulating the body’s natural immune system to treat patients with chronic inflammatory diseases, viral infections and cancer.

3,072 Listeners

1,982 Listeners

1,095 Listeners

2,373 Listeners

951 Listeners

802 Listeners

124 Listeners

339 Listeners

6,095 Listeners

91 Listeners

10,183 Listeners

568 Listeners

149 Listeners

249 Listeners

189 Listeners